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Abstract The objective of this study was to use data from
a noninterventional study to evaluate the eVectiveness of
adalimumab in rheumatoid arthritis (RA) patients during
routine clinical practice and to explore the potential impact
of patient and disease characteristics in response to ada-
limumab therapy. A total of 2,625 RA patients with speci-
Wed data at baseline (prior to initiating adalimumab
treatment) and 12 months entered this study between April
2003 and March 2009. We evaluated response to ada-
limumab therapy and conducted stepwise regression and
subgroup analyses of factors inXuencing therapeutic
response. During the 1-year adalimumab treatment period,
disease activity decreased from a baseline mean disease
activity score-28 joints (DAS28) of 5.9–3.9, while func-
tional capacity improved from 59.0 to 68.4 Funktions-
fragebogen Hannover (FFbH) percentage points. In
multivariate regression models, high baseline DAS28 was
the strongest positive predictor for decrease in disease
activity, and high baseline functional capacity was associ-
ated with reduced gains in functional capacity. Male gender
was a positive predictor of therapeutic response for both
disease activity and functional capacity, while older age
and multiple previous biologics were associated with a
reduced therapeutic response. Subset analyses provided fur-
ther support for the impact of baseline DAS28, FFbH, and
prior biologic therapy on therapeutic response during treat-
ment. We conclude that treatment with adalimumab leads
to decreased disease activity and improved function during
routine clinical practice. Patients with high disease activity
and low functional capacity are particularly beneWtted by
adalimumab therapy.
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Introduction
Rheumatoid arthritis (RA) is a chronic inXammatory dis-
ease characterized by progressive joint destruction. As their
joints deteriorate, patients experience pain and loss of func-
tion, often accompanied by decreased quality of life and
increased mortality. Tumor necrosis factor- (TNF-) is an
important cytokine that mediates inXammation in RA.
Introduction of TNF- inhibitors 10 years ago revolutionized
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biologic disease-modifying antirheumatic drugs (DMARDs).
Adalimumab, a human monoclonal antibody against
TNF-, is approved for RA treatment in the United States
(2002), the EU (2003), and other countries around the
world. Several clinical trials have shown that adalimumab
reduces the clinical symptoms of RA and decelerates
structural destruction of the joints, thus improving health-
related quality of life [1–6]. For optimal eVectiveness, ada-
limumab is usually given in combination with methotrexate
(MTX) [7].
Here, we present results of an ongoing noninterventional
study in which patients with active RA received 12 months
of adalimumab therapy. The objectives of this study were
to evaluate the eVectiveness of adalimumab in routine clini-
cal practice and to explore the potential impact of patient




This report utilizes data from a single-arm, multicenter,
prospective, observational, noninterventional study of RA
patients starting adalimumab therapy at their clinician’s
decision during routine clinical practice at 374 rheumatol-
ogy centers and clinical practices in Germany. After a base-
line visit (prior to initiation of adalimumab therapy),
follow-ups were scheduled at months 3, 6 and 12 during the
Wrst year of adalimumab treatment.
In this report, we present results for up to 12 months of
adalimumab therapy including all eligible patients who
enrolled between April 2003 and March 2009. The primary
objectives of this study were to evaluate the eVectiveness of
adalimumab in RA patients during routine clinical practice
and to explore the potential impact of patient and disease
characteristics in response to adalimumab therapy.
Patients in the adalimumab noninterventional study
were required to: (1) be at least 18 years of age with active
RA; (2) have a clinical indication for treatment with a
TNF- inhibitor and no contraindications; (3) have not
been given adalimumab previously; and (4) provide writ-
ten consent for participation. Patients who had received
prior treatment with TNF- inhibitors other than ada-
limumab were eligible for study inclusion. All patients
were informed about the objectives of the study and gave
written consent for their voluntary participation and the
anonymous use of their personal data in statistical analyses.
Because of the noninterventional, observational nature of
this study, ethics approval was not required by German
law.
All patients who had baseline documentation within
14 days of starting therapy, baseline DAS28 ¸ 3.2, and no
previous adalimumab therapy were eligible for study inclu-
sion (data analysis set). Because a primary goal of this
study was to evaluate factors that aVected therapeutic
response at 12 months, patients included in the regression
analysis set were required to have data documented for the
DAS28 and FFbH at baseline and at month 12 of follow-up.
In addition, patients with poor baseline documentation were
excluded.
RA treatment was performed according to routine clini-
cal practice, with adalimumab given subcutaneously at the
recommended dose of 40 mg every other week according to
label. Concurrent treatment with MTX was recommended
according to the German Summary of Product Characteris-
tics unless contraindicated.
Assessments of eVectiveness
RA disease activity and functional capacity in daily activi-
ties were selected as target variables of eVectiveness. Dis-
ease activity was assessed by the disease activity score-28
joints (DAS28). The DAS28 varies between 0 and 10, with
10 indicating the highest degree of disease activity [7, 8].
The Funktionsfragebogen Hannover (FFbH) question-
naire was used to assess patient function. The FFbH is a
self-administered patient questionnaire comprising 18
questions on functional capacity in activities of daily living
and is comparable to the health assessment questionnaire–
disability index (HAQ–DI) [9]. The numerically coded
responses to the questions are combined to provide a total
score that indicates the degree of remaining functional
capacity (with 0% indicating maximal impairment and
100% maximal functional capacity) [10].
Month 12 values for DAS28 and FFbH were used as
endpoints for eVectiveness.
Data analysis
Descriptive statistics or frequencies were computed for all
data as appropriate. Due to the documentary nature of this
noninterventional study, data were not available for all
assessments, and thus the sample size diVered among
parameters for each visit. All patients in the regression
analysis set had baseline and 12 month data for the main
outcome parameters (DAS28 and FFbH). For the data anal-
ysis set, supportive analyses using the last observation car-
ried forward (LOCF) method were conducted to determine
DAS28 and FFbH outcomes. LOCF analyses utilized the
last available data from all patients with a documented
withdrawal at or before month 12.
In contrast to randomized clinical trials, data collected in
a noninterventional observational study are not controlled123
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patient and disease characteristics. Since all RA patients
with the indication for adalimumab treatment were eligible
for our study, our cohort of patients was very heteroge-
neous in terms of disease and patient characteristics such as
disease duration and activity, comorbidities, concomitant
medication, and treatment history. Regression analysis is
the statistical method of choice to identify the relevant
treatment-modifying variables and to quantify their impact
on therapy outcome [11, 12].
Multiple regression analyses were utilized to evaluate
two diVerent endpoints: change in DAS28 from baseline to
month 12 and change in FFbH from baseline to month 12.
For each of the two measures of therapeutic response, a
regression model was built to identify variables that poten-
tially modiWed the therapeutic eVect. All 35 patients and
disease characteristics determined at baseline prior to treat-
ment with adalimumab were entered into each model using
a stepwise (forward selection and backward elimination)
technique. Only those variables (predictors) showing an
independent, statistically signiWcant contribution to the
respective endpoint (DAS28 or FFbH) at month 12 were
retained in the regression model for that endpoint. The
coeYcient of determination r2 and the beta weights indicate
the gain in explanatory power and the strength of inXuence,
respectively [13].
Based on the results of the regression analyses, explor-
atory subgroup analyses employing mean comparisons
were performed on relevant and statistically signiWcant
parameters to determine how these characteristics were
associated with therapeutic outcome.
Results
Baseline patient characteristics
The data analysis set consisted of 3,404 patients. Baseline
demographic and disease characteristics are presented in
Table 1. Patients had a mean age of 54.6 years, were mostly
(78%) women, exhibited moderate to high disease activity
(mean DAS28 of 5.9, range 3.4–8.3), and had a mean dis-
ease duration of 11.7 years. More than 90% of patients
received a diagnosis of RA more than 2 years before study
enrollment, and almost half of the patients received the
diagnosis more than 10 years ago.
Almost all (95.7%) patients had received prior therapy
with at least one conventional DMARD, mostly MTX
(83.0%). Approximately, 30% of the patients had been pre-
viously treated with at least one biologic agent and 6.8%
had received prior treatment with two or more biologic
agents. The most frequently used biologic agents were eta-
nercept (20.7%) and inXiximab (13.4%). Mean treatment
duration for prior biologic agents ranged from a mean of
12.6 months for anakinra to 15.3 months for inXiximab.
The most frequent reasons for discontinuation of biologic
agents were lack of eVectiveness (66.1%) and lack of toler-
ance (24.7%).
Regression analysis set
The regression analysis set consisted of patients with data
documented for the DAS28 and FFbH at baseline and at
month 12 of follow-up. A total of 779 patients withdrew
from the study at month 3 or month 6; these patients did
not have data at month 12 and therefore did not meet the
Table 1 Baseline characteristics of patients at the time of initiation of
adalimumab therapy
Data are presented as mean values (standard deviation [SD]) unless
otherwise indicated
BMI body mass index, COX-2 cyclo-oxygenase 2, CRP C-reactive
protein, DAS28 Disease Activity Score-28 joints, DMARD disease-
modifying antirheumatic drug, ESR erythrocyte sedimentation rate,
FFbH Funktionsfragebogen Hannover functional capacity question-
naire, NSAIDs nonsteroidal anti-inXammatory drugs, VAS visual
analog scale
Parameter Data analysis 




Age, years (SD) 54.6 (12.7) 54.6 (12.7)
Females, % 77.7 77.4
BMI, kg/m2 (SD) 26.0 (4.8) 25.9 (4.7)
Disease duration, years (SD) 11.7 (9.2) 11.7 (9.1)
Tender joint count (SD) 12.4 (7.2) 12.6 (7.2)
Swollen joint count (SD) 9.6 (6.2) 9.7 (6.2)
CRP, mg/L (SD) 33.3 (62.7) 33.4 (63.5)
ESR, mm/h (SD) 34.2 (23.0) 34.1 (22.7)
Rheumatoid factor 77.7 78.2
Erosive changes, % 77.1 77.5
Rheumatoid nodules, % 26.0 26.0
Joint replacement surgery, % 16.9 16.6
Patient global assessment-VAS (SD) 6.5 (1.8) 6.5 (1.8)
DAS28 (SD) 5.9 (1.2) 5.9 (1.1)
FFbH, % remaining 
functional capacity (SD)
58.3 (23.1) 59.0 (23.1)
Concomitant therapy
Any conventional DMARD, % 74.5 76.1
MTX, % 54.2 56.4
LeXunomide, % 21.1 20.4
Analgesics, % 26.2 25.5
NSAIDs (nonspeciWc), % 45.0 45.8
COX-2 inhibitors, % 20.7 21.2
Glucocorticoids, % 86.0 85.6123
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2,625). An additional 233 patients withdrew at 12 months.
Because complete data for month 12 were available for
these patients, they were included among the 2,625 patients
in the regression analysis set. The most frequent reasons
for withdrawal in the Wrst 12 months of therapy were
lack of eYcacy (538 patients) and adverse drug reactions
(247 patients).
Baseline characteristics for the data analysis set and
regression analysis set were similar (Table 1).
Impact of treatment on concomitant therapy
The proportions of patients receiving concomitant therapy
at the time of initiation of adalimumab therapy were similar
in the data analysis set and the regression analysis set
(Table 1). At the time of adalimumab treatment initiation,
approximately 75% of patients were receiving one or more
conventional DMARDs, mostly MTX or leXunomide. In
the regression analysis set, the percentage of patients with
concomitant DMARD therapy decreased to 69.7% after
12 months of treatment with adalimumab. However, the
percentage of patients receiving concomitant treatment
with MTX (as recommended) remained stable at 54.7%.
The percentage of patients taking leXunomide was reduced
by about one third during the same time interval (from 20.4
to 13.9%).
In the regression analysis set, the percentage of patients
receiving glucocorticoids in addition to adalimumab
decreased from 85.6% at baseline to 73.9% at month 12,
and the mean equivalent dose of prednisolone decreased
from 8.8 to 5.8 mg/day in the same time interval. The pro-
portion of patients with concomitant painkillers was
reduced for nonsteroidal anti-inXammatory drugs (NSA-
IDs; from 45.8 to 37.4%), cyclooxygenase-2 (COX-2)
inhibitors (from 21.2 to 13.3%), and analgesics (from 25.5
to 16.6%).
Impact of treatment on disease activity and functional 
capacity
In the regression analysis set, disease activity decreased
(from a mean DAS28 score of 5.9–3.9) and functional
activity improved (from a mean FFbH score of 59.0–68.4%
points; higher FFbH scores indicate greater functional
capacity) during the Wrst 12 months of adalimumab treat-
ment (Fig. 1; Table 2). Outcomes were similar when the
1,012 patients with documented withdrawals were included
in LOCF analyses of the data analysis set (N = 3,404;
Table 2). Mean DAS28 scores decreased from 5.9 to 4.2 at
month 12 in the data analysis set and mean FFbH scores
increased from 58.3 to 65.7% points. However, compared
to the regression analysis set, mean DAS28 scores in the
data analysis set were slightly higher at month 12 (4.2 vs.
3.9) and mean FFbH scores were slightly lower (65.7 vs.
68.4% points), consistent with the observation that lack of
eYcacy accounted for the largest proportion of withdraw-
als.
The greatest improvements in disease activity and func-
tional capacity occurred during the Wrst 3 months of ada-
limumab therapy (Fig. 1). Mean DAS28 and FFbH scores
continued to improve at 6 months and were sustained
throughout 12 months. The DAS28 and FFbH scores dis-
played a low correlation throughout the course of the study
(r = ¡0.41 at baseline and ¡0.5 at month 12).
At 12 months, 19.1% of patients in the regression analysis
set were in clinical remission, deWned as DAS28 <
2.6 points [14], 41.9% of patients had experienced a
clinically relevant functional improvement, deWned as
an individual FFbH increase of 11 or more percentage points
from baseline [15], and 57.8% were functionally independent
(FFbH ¸ 67% points) [16] (Table 2). However, 9.1% of
patients experienced a clinically signiWcant decrease in func-
tional capacity (FFbH decrease of at least 11% points) during
this time period. The proportions of patients with clinical
improvements were slightly lower in the data analysis set
(Table 2).
Patient and disease characteristics with an inXuence 
on therapeutic eVectiveness
In the regression model for disease activity (N = 2,625), 8
of the 35 tested variables showed a signiWcant partial corre-
lation with changes in DAS28 at month 12 and therefore
can be regarded as having an impact on eVectiveness in
terms of disease activity (Table 3). Among these vari-
ables, baseline DAS28 exerted the strongest inXuence on
therapeutic gain. High DAS28 baseline values correlated
with reduced DAS28 values at month 12 and thus had a
positive impact on reduction in disease activity. The additional
Fig. 1 Therapeutic response to adalimumab in patients in the regres-
sion analysis set (N = 2,625)123
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nounced. Other variables with a positive eVect on
reduced disease activity were high FFbH scores at base-
line, concomitant MTX therapy, and male gender. Previ-
ous biologic treatment, older age, increased number of
tender joints, and use of nonselective NSAIDs were
associated with reduced therapeutic gain as assessed by
DAS28.
The 11 parameters that modiWed the increase in func-
tional capacity at month 12 (Table 4) were only partially
identical with the ones associated with reduced disease
activity. The strongest inXuence was exerted by baseline
FFbH scores; high functional capacity at baseline was asso-
ciated with a less pronounced increase of FFbH. Accord-
ingly, patients with low functional capacity at baseline were
more likely to achieve functional improvements during ada-
limumab treatment. Variables with less pronounced eVects
that were associated with reduced functional improvement
were disease duration, previous joint replacement surgery,
older age, previous biologic therapies, and high body mass
index (BMI). Employment, male gender, use of COX-2
inhibitors, ESR levels, and baseline global patient assess-
ment had a positive inXuence on increases in functional
capacity.
No signiWcant partial correlation with the two endpoints
of therapeutic outcome was found for CRP levels, subjec-
tive pain experience, subjective limitations, number of con-
comitant DMARD therapies, duration of previous DMARD
therapies, erosive changes, or concomitant diseases.
Accordingly, we conclude that these characteristics do not
independently contribute to therapy success or failure.
Analysis of selected patient subgroups
Subgroup analysis was performed on selected signiWcant
parameters to illustrate how these patient and disease char-
acteristics impact therapeutic outcome. When classiWed
into patients with high or moderate/low disease activity
(baseline DAS28 value >5.1 and ·5.1, respectively), the
group of patients with high baseline DAS28 values experi-
enced a larger reduction in mean disease activity (from a
mean DAS28 of 6.4–4.2 over 12 months) than the group
with moderate/low baseline DAS28 (from a mean DAS28
of 4.4–3.2).
A similar pattern was seen for patient function. When
patients were classiWed by baseline FFbH scores, patients
with higher physical impairment (baseline FFbH score
·50% points) improved from a mean of 34.2–50.9 points
during 12 months of treatment with adalimumab, while
those with less impairment (baseline FFbH score >50%
points) had much lower levels of improvement (from a
mean of 73.9–78.9 points). Despite the greater extent of
improvement, patients with high disease activity and low
functional capacity at baseline did not reach the DAS28 and
FFbH levels of the groups of patients with better baseline
values.
Previous biologic treatment was associated with less
pronounced therapeutic success of adalimumab for both
Table 2 Disease activity (DAS28) and functional capacity (FFbH) at baseline, month 3, and month 12 in the data analysis set (N = 3,404, last
observation carried forward) and the regression analysis set (N = 2,625)
DAS28 Disease Activity Score-28 joints, FFbH Funktionsfragebogen Hannover functional capacity questionnaire, SD standard deviation
* Month 3 regression analysis set data consisted of 2,421 patients for DAS28 analyses and 2,484 patients for FFbH analyses
Outcome Month after inclusion (selection)
Data analysis set (N = 3,404) Regression analysis set (N = 2,625)*
Baseline Month 3 Month 12 Baseline Month 3 Month 12
DAS28
Mean DAS28 (SD) 5.9 (1.2) 4.5 (1.5) 4.2 (1.5) 5.9 (1.1) 4.2 (1.4) 3.9 (1.4)
% of patients in remission (DAS28 < 2.6) 0.0 11.4 16.2 0.0 14.1 19.1
FFbH
Mean FFbH percentage points (SD) 58.3 (23.1) 65.1 (23.5) 65.7 (24.1) 59.0 (23.1) 67.8 (22.7) 68.4 (23.5)
% of patients with clinically relevant 
FFbH changes (§11% points) compared to baseline
Clinically relevant improvement (¸11% points) – 32.4 36.8 – 38.3 41.9
Clinically relevant deterioration (¸¡11% points) – 6.8 11.0 – 5.6 9.1
No clinically relevant change (<§11% points) – 60.7 52.1 – 56.1 49.0
% of functionally independent patients
(FFbH ¸ 67% points) 38.4 52.3 52.8 39.5 57.0 57.8123
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DAS28 Disease Activity Score-28 joints, FFbH Funktionsfragebogen Hannover functional capacity questionnaire, MTX methotrexate, NSAIDs
nonsteroidal anti-inXammatory drugs
a High DAS28 values indicate high disease activity. bHigh FFbH values indicate high functional capacity (low impairment)
Regression model DAS28, N = 2,625 Model values
Constant Total R² P-value
1.524 0.2118 <0.001
Variable Value Beta-weight Partial r2 P-value
Positive predictors for decrease in disease activity
Baseline DAS28a Continuous (0–10 units) ¡0.707 0.156 <0.001
Baseline FFbHb Continuous (0–100% points) ¡0.006 0.008 <0.001
Concomitant MTX 1 = yes, 0 = no ¡0.161 0.003 0.0013
Gender 1 = male, 0 = female ¡0.182 0.003 0.0027
Negative predictors for increase in disease activity
Previous biologics Number (0, 1, 2, 3, 4) 0.314 0.020 <0.001
Age (years) Continuous 0.012 0.014 <0.001
Tender joint count Number (0–28) 0.024 0.006 <0.001
NSAIDs (nonselective) 1 = yes, 0 = no 0.140 0.002 0.0056
Table 4 Parameters with signiWcant partial correlation with FFbH changes at month 12 in the regression analysis set
BMI body mass index, COX-2 cyclo-oxygenase 2, ESR erythrocyte sedimentation rate, FFbH Funktionsfragebogen Hannover functional capacity
questionnaire, MTX methotrexate
a High FFbH values indicate high functional capacity (low impairment)
Regression model FFbH, N = 2,625 Model values
Constant Total R² P-value
36.647 0.205 <0.001
Variable Value Beta-weight Partial r2 P-value
Positive predictors for increase in functional capacity
Employment 1 = yes, 0 = no 3.078 0.023 <0.001
Gender 1 = male, 0 = female 3.160 0.005 <0.001
COX-2 inhibitors 1 = yes, 0 = no 2.892 0.005 <0.001
ESR Continuous 0.047 0.004 <0.001
Patient global assessment Number (0–10) 0.653 0.003 <0.001
Negative predictors for increase in functional capacity
Baseline FFbHa Continuous (0–100% points) ¡0.317 0.126 <0.001
Disease duration Continuous ¡0.171 0.017 <0.001
Joint replacement 1 = yes, 0 = no ¡4.277 0.008 <0.001
Age (years) Continuous ¡0.123 0.005 <0.001
Previous biologics Number (0, 1, 2, 3, 4) ¡2.149 0.005 <0.001
BMI (kg/m²) Continuous ¡0.258 0.005 <0.001123
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into subgroups by the number of previous biologic thera-
pies, patients with 3 previous biologic therapies had higher
DAS28 values at baseline compared with patients with 1 or
0 previous biologic therapies. While all subgroups showed
a decrease in DAS28 values during the 12 months of ada-
limumab treatment, this decrease was most pronounced in
patients without previous biologic treatment and least pro-
nounced in those with 2 or 3 previous biologic therapies
(Fig. 2). The eVect of prior biologic therapy was also evi-
dent when analyzing functional capacity. Patients without
previous biologic treatment showed the highest baseline
FFbH values (60.9% points) and improved to 70.7% points
at month 12. With increasing numbers of previous biologic
therapies, FFbH baseline and month 12 scores declined
steadily. Patients with 3 previous biologic therapies had a
mean FFbH baseline value of 48.8% points and gained only
4.4% points (to 53.2% points) by month 12.
Discussion
In this study, we evaluated outcomes of RA patients treated
with adalimumab in routine clinical practice. During the
1-year treatment period, adalimumab reduced disease activity
and increased functional capacity (Fig. 1). These changes
were evident at month 3 and were maintained throughout
the 12-month observation period.
Compared to other adalimumab studies, this study is dis-
tinct with respect to its size and observational, noninterven-
tional nature. Noninterventional observational studies and
registries include large numbers of patients that are hetero-
geneous in terms of disease activity, disease duration, age,
treatment history, and other patient and disease characteris-
tics. The lack of speciWed entry criteria greatly expands the
population of patients included in noninterventional stud-
ies. Zink et al. reported that only 27–28% of patients
enrolled in the German biologics register were eligible for
the major randomized adalimumab trials. Furthermore,
response rates were lower among patients in the register
who would not have been eligible for inclusion in random-
iszd clinical trials [17]. Observational studies are thus
important tools that allow knowledge concerning treatment
eVects to be transferred to conditions of routine clinical
practice.
Because the evaluation of factors aVecting treatment
response at 12 months was a primary goal of the study, we
focused primarily on patients who had DAS28 and FFbH
data at baseline and 12 months. This approach has been
successfully used in analyses of data from the German biol-
ogics register, RABBIT [11]. The treatment response
observed in this study is generally comparable with those
from other studies of adalimumab therapy in smaller RA
patient populations [18–20].
Large numbers of patients are required for the identiWca-
tion of characteristics that modify disease progression and
therapeutic response by post hoc multivariate regression
analysis. This condition was met in our study, which
included 2,625 patients with data at baseline and month 12.
High disease activity was correlated with the greatest
decrease in DAS28 at month 12 (Table 3), and high func-
tional capacity was a strong negative predictor of increased
functional capacity during treatment (Table 4), indicating
that baseline patient disease status has substantial eVects in
response to treatment. Male gender was a positive predictor
for therapeutic response for both disease activity and func-
tional capacity, whereas previous biologic therapy and
older age were negative predictors of therapeutic response
for both analyses. Other predictors of therapeutic response
were unique to DAS28 changes, including TJC, concomi-
tant MTX, and concomitant NSAIDs, or to FFbH changes,
including employment, patient global assessment, and ESR.
Baseline FFbH was selected in both models, but served as a
positive predictor for DAS28 decreases and a negative pre-
dictor for increased functional capacity. Although some of
these variables, particularly male gender, previous biologic
therapy, and age, have been found to be signiWcant predic-
tors of response or remission in RA [21–23], TJC has not
previously been associated with therapeutic response. The
negative impact of tender joints on DAS28 scores at 12
months was an unexpected Wnding, as the TJC is a pivotal
component of the DAS28 and high DAS28 baseline values
were correlated with strong improvements in disease activ-
ity. This eVect was not observed for swollen joints. The
association between tender joint count and DAS28 changes
requires further exploration. Another issue that deserves
additional study is the impact of NSAID use on response.
Fig. 2 DAS28 during adalimumab treatment by number of previous
biologic therapies in the regression analysis set (N = 2,625). Patient
numbers at month 0, 3, 6, 12. 0 previous biologic: n = 1,834, 1,760,
1,671, 1,834. 1 previous biologic: n = 623, 560, 557, 623. 2 previous bi-
ologics: n = 154, 141, 140, 154. 3 previous biologics: n = 14, 14, 12, 14123
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of a positive therapeutic response [21, 22], whereas our
Wndings suggest that NSAID use is associated with a nega-
tive therapeutic response as assessed by DAS28.
Subgroup analyses were used to further explore thera-
peutic response patterns. These analyses supported the
observation that patients with high disease activity and low
functional capacity beneWtted substantially from ada-
limumab therapy. Despite the excellent clinical response
observed in these patients, though, they did not achieve the
same DAS28 and FFbH levels as patients with better values
at baseline. The eVect of previous biologic treatment on the
therapeutic success of adalimumab was also supported by a
subgroup analysis (Fig. 2); patients with 2 or 3 previous
biologic therapies showed only small DAS28 reductions,
despite the fact that these groups of patients had high base-
line DAS28 values, a parameter associated with improved
therapeutic response. This Wnding calls into question the
strategy of continuous cycling among diVerent anti-TNF
treatments. In a study in which patients with inadequate
response to TNF inhibitors were treated with tocilizumab,
an interleukin-6 receptor inhibitor, patients receiving the
highest dose of tocilizumab showed similar ACR20
response rates irrespective of the number of failed anti-
TNF- therapies [24]. Therefore, switching to a biologic
agent with a diVerent mode of action may be a preferable
option under certain conditions.
The positive impact of concomitant MTX treatment on
therapeutic response to adalimumab has been demonstrated
in clinical trials, mainly in those involving MTX-naïve
patients with early RA [1, 2, 25], but has not been studied
as thoroughly in patients with longstanding RA and multi-
ple DMARD exposure. The association between concomi-
tant MTX and reduced disease activity shown here provides
an important argument in favor of MTX plus adalimumab
combination therapy, even in patients with longstanding
disease.
On the basis of these data, we conclude that adalimumab
therapy is eVective in reducing disease activity and improv-
ing function in “real-world” RA patients during routine
clinical practice. Patients with high disease activity and low
functional capacity are particularly likely to beneWt from
initiation of adalimumab, but those who are older or have
been treated with multiple biologic agents may experience
a lower degree of improvement.
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